Innovus Pharmaceuticals (INNV) announced that the U.S. Food and Drug Administration has approved abbreviated new drug application, or ANDA, No. 208024 for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray owned by Akorn (AKRX). Innovus has a manufacturing and supply agreement with Akorn for the supply of FlutiCare. In December 2015, Innovus Pharma acquired Novalare FP, Inc. and changed its name to Novalere and pursuant to that transaction, the company acquired the rights to receive FlutiCare supply from Akorn following ANDA approval. On April 17, the FDA approved the ANDA and Akorn alerted the company of the approval. While waiting for ANDA approval, Innovus Pharma announced an alternative source of supply for its FlutiCare product through its commercial partnership with a third party supplier on May 9, 2017. Since that time, the company has procured its supply of FlutiCare pursuant to ANDA No. 207957 through this third party supplier. Innovus Pharma currently has secured two batches of its FlutiCare product from this entity. In addition, Innovus Pharma announced that it has reached a sales milestone with its sale of at least 1,000 units of FlutiCare per day through its various sales channels.
https://thefly.com/landingPageNews.php?id=2894769
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.